Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

← catalyst calendar

NCT06535607 · readout in 834 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

257estimated

Sites

Countries

Australia, Brazil, Canada +9

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-08-22

actual

When the study began enrolling

Primary completion

2028-11-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-11-30

estimated

The whole study's end, after follow-up

First posted

2024-08-02

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-06

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)
Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)

Interventions

Biological: Volrustomig
Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Drug: 5-FU

Primary outcomes

what the primary-completion date above is the date OF

Objective response rate (ORR)

measured Through study completion, an average of 4 years

The number of participants with adverse events/serious adverse events

measured Through study completion, an average of 4 years

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed